Mizuho analyst Ann Hynes raised the firm’s price target on CVS Health (CVS) to $95 from $88 and keeps an Outperform rating on the shares, telling investors that the company provided “several positive updates” at its bi-annual investor day, including updated 2025 guidance, detailed 2026 guidance, and a raised long-term earnings growth outlook. CVS is the top pick in the analyst’s coverage universe, the analyst noted.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS: